Clinical Trial Update: A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase I study evaluating panobinostat (LBH589) in combination with external beam radiotherapy for prostate cancer, esophageal cancer, and head and neck cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Head and Neck Cancer
• Prostate Cancer

Drugs mentioned

• LBH589 (panobinostat) (panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer, Head & Neck Cancer | Phase 1 | Status: COMPLETED